Print Page | Contact Us | Sign In | Join
Industry News: News

Galderma Announces Positive Test Results for Investigational Botulinum Toxin

Thursday, October 10, 2019   (0 Comments)
Share |

Galderma recently announced the Phase 2 clinical trial results for its novel ready-to-use investigational botulinum toxin, QM1114. The multicenter, randomized, double-blind, placebo-controlled study successfully demonstrated the safety and efficacy of Galderma's liquid formulation of botulinum toxin type A for the treatment of glabellar lines (frown lines). The Phase 3 clinical trial program will begin soon to support regulatory submissions globally.

Read more at PR Newswire >>

Contact Us

224 N Desplaines, Ste. 300
 Chicago, IL 60661

Phone: 312-981-0993

Fax: 888-827-8860


AmSpa provides legal, compliance, and business resources for medical spas and medical aesthetic practices.

Follow Us: